SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

PHVS

Pharvaris N.V.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

With strong Phase 3 data and NDA submission imminent, PHVS is positioned for potential approval and commercialization catalysts in 2026–2027. Traders should monitor FDA feedback and upcoming CHAPTER-3 data, which could further validate the prophylactic indication and expand market potential.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$28.00
T+0 close · Mar 2, 2026 · via day close
Latest settled
+6.71%
T+60 · $29.88
Vs SPY
−2.61%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $28.00entry
  2. T+1 · 9mo ago −4.38%α −3.46% · $26.78
  3. T+5 · 8mo ago −5.32%α −4.11% · $26.51
  4. T+20 · 8mo ago −2.54%α +5.40% · $27.29
  5. T+60 · 6mo ago +6.71%α −2.61% · $29.88
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris presented positive Phase 3 RAPIDe-3 and long-term CHAPTER-1 trial data for deucrictibant, an oral B2 receptor antagonist for treating and preventing hereditary angioedema (HAE) attacks. The drug demonstrated rapid symptom relief (1.28 hours), complete resolution in 11.95 hours, and sustained efficacy with once-daily dosing, supporting its potential as a best-in-class oral therapy. No safety signals were observed over nearly three years of use.

Key Facts

  • RAPIDe-3 Phase 3 trial met primary and all 11 secondary endpoints for on-demand treatment of HAE attacks with deucrictibant.
  • Median time to symptom relief: 1.28 hours (vs. >12 hours placebo); complete resolution in 11.95 hours (vs. >48 hours placebo).
  • CHAPTER-1 open-label extension showed sustained efficacy over ~3 years: attack rate dropped from 2.18 to 0.12 attacks/month; ~50% of patients attack-free.
  • Deucrictibant was well tolerated with no treatment-related serious adverse events or discontinuations.
  • Pharvaris is preparing an NDA submission for the immediate-release capsule in H1 2026; topline data from the pivotal CHAPTER-3 prophylaxis trial expected Q3 2026.

Financial Impact

Potential blockbuster drug profile with oral convenience and injectable-like efficacy could position deucrictibant as standard of care, significantly increasing valuation if approved.

revenuemarketCapeps

Risk Factors

  • Regulatory delays or rejection of NDA submission despite positive data.
  • Competition from existing injectable and oral HAE therapies (e.g., Takhzyro, Kalbitor, Orladeyo).
  • Failure to replicate results in ongoing CHAPTER-3 trial for prophylaxis.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247196

Track record

51 reports on PHVS

Performance horizon

15 of 17 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026